For unclear reasons, mutations in KRAS are more common in pancreatic (80%–90%), colorectal (40%–60%), and lung cancers (30%); in contrast, mutations are rarely found in breast (1%–2%) and head and neck cancers (1%) (56–58). Here, KRAS is linked to lung carcinoma.